Senzime AB 

$0.3491
8
-$0.05-12.73% Wednesday 19:16

Statistics

Day High
0.39
Day Low
0.39
52W High
0.7227
52W Low
0.3275
Volume
6,970
Avg. Volume
7,806
Mkt Cap
54.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.25
-0.19
-0.14
-0.08
Expected EPS
N/A
Actual EPS
N/A

Financials

-131.99%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
10.95MRevenue
-14.45MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNZZF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap120.46B
Medtronic offers patient monitoring systems that compete with Senzime's TetraGraph monitor, especially in the neuromuscular monitoring segment.
Koninklijke Philips N.V.
PHG
Mkt Cap25.31B
Philips has a broad range of healthcare products, including patient monitoring solutions that compete with Senzime's offerings.
GE Aerospace
GE
Mkt Cap349.78B
General Electric, through its healthcare division, provides a range of patient monitoring systems that compete with Senzime's technologies.
Boston Scientific
BSX
Mkt Cap69.27B
Boston Scientific offers medical devices that, while more focused on interventional medical specialties, still compete in the broader market for patient monitoring.
Baxter International
BAX
Mkt Cap13.35B
Baxter International offers a range of medical devices and patient monitoring systems that can be seen as competitors to Senzime's products.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its medical devices segment, competes in the surgical and patient monitoring markets, overlapping with Senzime's target market.
Smith & Nephew
SNN
Mkt Cap12.08B
Smith & Nephew, while primarily focused on orthopedics, also offers products that can compete in the surgical solutions and monitoring space.
Abbott Laboratories
ABT
Mkt Cap187.45B
Abbott Laboratories provides a wide range of healthcare products, including patient monitoring devices, competing with Senzime's portfolio.
Stryker
SYK
Mkt Cap116.27B
Stryker specializes in medical and surgical equipment, including patient monitoring technologies, making it a competitor to Senzime.

About

Based in Uppsala, Sweden, Senzime AB (publ) is a medical technology company founded in 1999, specializing in the development and commercialization of advanced patient monitoring systems. These systems are designed to oversee individuals under anesthesia across a wide geographic reach, including Europe, Oceania, Asia, Canada, and the United States. A key offering is the TetraGraph monitor, which precisely stimulates, measures, analyzes, and displays muscle function for surgical patients administered neuromuscular blocking agents. The system includes the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. Its TetraConnect data management portal allows clinicians to easily access, view, and export records from the TetraGraph in PDF or Excel format. Additionally, TetraGraph Device Connectivity facilitates the transfer of data from the monitor to other patient monitoring systems. A specific TetraGraph Philips Interface enables the direct transmission of neuromuscular monitoring parameters (TOFC, TOFR, PTC, and TOF bars) to Philips patient monitors, displaying readings on the Philips Intellivue Monitor. The company's portfolio also includes the CliniSenz Analyzer, developed for continuous postoperative patient surveillance in hospital settings. Furthermore, the Onzurf Probe is a sterile, CE-marked, single-use micro-dialysis product that allows for continuous sampling from gastrointestinal organs like the esophagus, stomach, and liver. Senzime AB (publ) has entered into a strategic license and connectivity agreement with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to connect directly with Masimo's Root monitoring system and its digital hubs for seamless integration with hospital clinical information systems and electronic health records.
Show more...
CEO
Philip Siberg
Employees
58
Country
Sweden
ISIN
SE0002478776
WKN
000A0X93V

Listings

0 Comments

Share your thoughts

FAQ

What is Senzime AB stock price today?
The current price of SNZZF is $0.35 USD — it has decreased by -12.73% in the past 24 hours. Watch Senzime AB stock price performance more closely on the chart.
What is Senzime AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Senzime AB stocks are traded under the ticker SNZZF.
Is Senzime AB stock price growing?
SNZZF stock has fallen by -12.73% compared to the previous week, the month change is a -10.49% fall, over the last year Senzime AB has showed a -50.5% decrease.
What is Senzime AB market cap?
Today Senzime AB has the market capitalization of 54.88M
When is the next Senzime AB earnings date?
Senzime AB is going to release the next earnings report on October 29, 2026.
What is Senzime AB revenue for the last year?
Senzime AB revenue for the last year amounts to 10.95M USD.
What is Senzime AB net income for the last year?
SNZZF net income for the last year is -14.45M USD.
How many employees does Senzime AB have?
As of September 08, 2026, the company has 58 employees.
In which sector is Senzime AB located?
Senzime AB operates in the Health & Wellness sector.
When did Senzime AB complete a stock split?
Senzime AB has not had any recent stock splits.
Where is Senzime AB headquartered?
Senzime AB is headquartered in Uppsala, Sweden.